Alvespimycin

  • 1 lab in 1 country
  • Funders: American Federation for Aging Research and 3 more
  • Animals1

Outcomes

2

CDKN2A

downin mice1

1 study
  1. Alvespimycin decreases CDKN2A in mice.

    “delayed the onset of several age-related symptoms and reduced p16INK4a expression”

    Animalsin Ercc1 -/∆ progeroid mice

    Identification of HSP90 inhibitors as a novel class of senolytics

    Nature communications4 Sep 2017

More on CDKN2A

Healthspan

upin mice1

1 study
  1. Alvespimycin improves healthspan in mice.

    “Treatment of Ercc1 -/∆ mice, a mouse model of a human progeroid syndrome, with the HSP90 inhibitor 17-DMAG extended healthspan”

    Animalsin Ercc1 -/∆ progeroid mice

    Identification of HSP90 inhibitors as a novel class of senolytics

    Nature communications4 Sep 2017

Latest